Combination therapy in recent onset rheumatoid arthritis: A randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine

Journal of Rheumatology

Volumn 25, Issue 8, 1998, Pages 1493-1498

  Van Den Borne, Ben E E M ^a   Landewé, Robert B M ^b   Goei The, Henk S ^b   Rietveld, Jobn H ^c   Zwinderman, Aelko H ^a   Bruyn, George A W ^d   Breedveld, Ferdinand C ^a   Dijkmans, Ben A C ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Wever Hospital Heerlen

^c Sandoz BV Uden

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chloroquine; Combination therapy; Cyclosporine; Rheumatoid arthritis

Indexed keywords

CHLOROQUINE; CYCLOSPORIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031950509     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
2. Harris ED. The rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996;23 Suppl 44:2-4.
3. Wilske KR, Yocum DE. Rheumatoid arthritis: the status and future of combination therapy. J Rheumatol 1996;23 Suppl 44:1.
4. Furst DE. Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. J Rheumatol 1996;23 Suppl 44:86-90.
5. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
6. Zvaifler NJ. Rheumatoid arthritis. The multiple pathways to chronic synovitis. Lab Invest 1995;73:307-10.
7. Dijkmans BA, de Vries E, de Vreede TM. Synergistic and additive effects of disease modifying anti-rheumatic drugs combined with chloroquine on the mitogen-driven stimulation of mononuclear cells. Clin Exp Rheumatol 1990;8:455-9.
8. Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992;19:1353-7.
9. Landewe RB, Miltenburg AM, Verdonk MJ, et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 1995;102:144-51.
10. Boers M, Dijkmans BA, van Rijthoven AW, Goei The HS, Cats A. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 1990;17:38-42.
11. Feutren G, Mihatsch MJ. Risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992;326:1654-60.
12. Landewe RB, Dijkmans BA, van der Woude FJ, Breedveld FC, Mihatsch MJ, Bruijn JA. Longterm low dose cyclosporine in patients with rheumatoid arthritis: Renal function loss without structural nephropathy. J Rheumatol 1996;23:61-4.
13. Rodriguez F, Krayenbuhl JC, Harrison WB, et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A - An update from the International Kidney Biopsy Registry. Arthritis Rheum 1996;39:1491-8.
14. Landewe RB, Vergouwen MS, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA. Antimalarial drug induced decrease in creatinine clearance. J Rheumatol 1995;22:34-7.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Ritchie DM, Boyle JA, Mclnnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
18. Boers M, Tugwell P, Felson DT, et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;21 Suppl 41:86-9.
19. Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305-9.
20. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Esdaile JM, Suissa S, Shiroky JB, et al. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med 1995;98:156-68.
22. Landewe RB, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-43.
23. Landewe RB, Goei The HS, van Rijthoven AW, Rietveld JR, Breedveld FC, Dijkmans BA. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994;21:1631-6.
24. Dijkmans BA. Safety aspects of cyclosporin in rheumatoid arthritis. Drugs 1995;50:41-7.